Skip to content
ETopical – Lifestyle
Author:
Telix Pharmaceuticals Limited
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
September 1, 2026
Telix Appoints David Gill as Chair
August 31, 2026
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
August 19, 2026
Telix to Host R&D Day in New York City on September 22, 2026
August 5, 2026
Telix H1 2026 Results: Investor Webcast Notification
July 30, 2026
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
July 21, 2026
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
July 20, 2026
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
July 20, 2026
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
July 15, 2026
1
2
3
Next Page
→